TRVN Trevena Inc.

2.6
+0.38  (+17%)
Previous Close 2.22
Open 2.22
52 Week Low 0.46
52 Week High 3.68
Market Cap $398,760,903
Shares 153,369,578
Float 152,264,371
Enterprise Value $352,091,902
Volume 16,677,019
Av. Daily Volume 12,639,988
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
TRV027
COVID-19
Phase 1b
Phase 1b
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
Oliceridine (TRV130)
Moderate to severe acute pain
Approved
Approved
FDA Approval announced August 7, 2020.
TRV250
Acute migraine
Phase 1
Phase 1
Phase 1 enrolment has been paused due to COVID-19 - noted March 26. 2020.
TRV734
Opioid use disorder
Phase 2
Phase 2
Proof of concept trial initiation announced December 23, 2019.
TRV027 - BLAST-AHF
Acute heart failure
Phase 2a
Phase 2a
Phase 2b endpoints not met - May 2016

Latest News

  1. - H.C. Wainwright: 22nd Annual Global Investment Conference -
    September 14th

    - Cantor Fitzgerald Virtual Global Healthcare Conference -
    September 17th

    -Oppenheimer Fall Healthcare Life Sciences & MedTech Summit -
    September 23rd

    CHESTERBROOK, Pa., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:

    H.C. Wainwright: 22nd Annual Global Investment Conference
    Title:Trevena (TRVN) Fireside

    - H.C. Wainwright: 22nd Annual Global Investment Conference -

    September 14th

    - Cantor Fitzgerald Virtual Global Healthcare Conference -

    September 17th

    -Oppenheimer Fall Healthcare Life Sciences & MedTech Summit -

    September 23rd

    CHESTERBROOK, Pa., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:

    H.C. Wainwright: 22nd Annual Global Investment Conference
    Title:Trevena (TRVN) Fireside Chat 
    Date:Monday, September 14th, 2020
    Time:2:00 – 2:20 p.m. Eastern Time
    Presenters:Carrie Bourdow, President & Chief Executive Officer
     Mark Demitrack, M.D., SVP & Chief Medical Officer
      
    Cantor Fitzgerald Virtual Global Healthcare Conference
    Title:Trevena (TRVN) Fireside Chat
    Date:Thursday, September 17th, 2020
    Time:2:00 – 2:30 p.m. Eastern Time
    Presenter:Carrie Bourdow, President & Chief Executive Officer
      
    Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
    Title:Trevena (TRVN) Virtual Presentation
    Date:Wednesday, September 23rd, 2020
    Time:11:40 a.m. – 12:20 p.m. Eastern Time
    Presenter:Bob Yoder, SVP & Chief Business Officer

    Webcast Links:

    A replay of the webcast will be accessible on the Events page of the Investors section on the Company's website at https://www.trevena.com/investors/events-presentations/ir-calendar.

    About Trevena

    Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

    For more information, please visit www.Trevena.com 

    Forward-Looking Statements

    Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "objective," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," "ongoing," or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Company's clinical trials or any future trials of any of the Company's investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company's assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Company's intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

    For more information, please contact:

    Investor Contact:

    Dan Ferry

    Managing Director

    LifeSci Advisors, LLC



    (617) 430-7576

    Company Contact:

    Bob Yoder

    SVP and Chief Business Officer

    Trevena, Inc.

    (610) 354-8840 

    Primary Logo

    View Full Article Hide Full Article
  2. --

    Publication in Anesthesiology: Favorable benefit-risk profile for OLINVYK (oliceridine) injection as measured by clinical utility function analysis

    Publication in Clinical Drug Investigation: Lower incidence of respiratory depression associated with OLINVYK as measured by frequency / duration of dosing interruption

    --

    CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two publications of the respiratory safety data from the OLINVYK development program. Both publications highlight data showing an improved respiratory safety profile for…

    --

    Publication in Anesthesiology: Favorable benefit-risk profile for OLINVYK (oliceridine) injection as measured by clinical utility function analysis

    Publication in Clinical Drug Investigation: Lower incidence of respiratory depression associated with OLINVYK as measured by frequency / duration of dosing interruption

    --

    CHESTERBROOK, Pa., Aug. 26, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two publications of the respiratory safety data from the OLINVYK development program. Both publications highlight data showing an improved respiratory safety profile for OLINVYK compared to IV morphine.

    "These two publications add to the comprehensive safety database of peer-reviewed published literature for OLINVYK," said Mark Demitrack, M.D., Senior Vice President and Chief Medical Officer of Trevena, Inc. "We believe these data will provide important information to clinicians and other healthcare decision-makers in managing acute pain patients in the hospital setting."

    1.) Benefit and Risk Evaluation of Biased μ-Receptor Agonist Oliceridine versus Morphine, by lead author Albert Dahan, M.D., Ph.D., Professor of Anesthesiology, Leiden University Medical Center.

    (https://doi.org/10.1097/ALN.0000000000003441)

    Study Summary and Key Findings:

    • A clinical utility function analysis was conducted on the ventilatory response to hypercapnia (VRH) data from the OLINVYK Phase 1 study. VRH is a validated measure of respiratory function, and opioid medications are known to interfere with the body's normal respiratory drive in response to elevated CO2 levels (hypercapnia). Clinical utility function analysis integrates the relative probability of analgesia and respiratory depression over the therapeutic plasma concentration range of a medication.

        
    • OLINVYK was associated with a higher probability of analgesia than respiratory depression, while the reverse was true for morphine.



    • The clinical utility function model predicted there would be a lower probability of a respiratory event occurring with OLINVYK versus morphine.



    • Over the clinically relevant concentration range, OLINVYK had a higher probability of providing analgesia than producing respiratory depression, while morphine had a higher probability of producing respiratory depression than providing analgesia.

    2.) Evaluating the Incidence of Opioid-Induced Respiratory Depression Associated with Oliceridine and Morphine as Measured by the Frequency and Average Cumulative Duration of Dosing Interruption in Patients Treated for Acute Postoperative Pain, by lead author Sabry Ayad, M.D., Department of Anesthesiology at Cleveland Clinic.

    (https://link.springer.com/article/10.1007%2Fs40261-020-00936-0)

    Study Summary and Key Findings:

    • In a secondary analysis of two Phase 3 randomized controlled trials using PCA dosing in orthopedic and plastic surgeries, the rate of dosing interruptions due to a respiratory safety event and average cumulative duration of interruptions was reported for both OLINVYK and IV morphine.



    • In both studies, the proportion of patients with dosing interruptions was higher with morphine 1 mg (17.1% in orthopedic surgery and 25.6% in plastic surgery) compared to OLINVYK 0.35 mg (7.6% in orthopedic surgery, 20.3% in plastic surgery) and 0.5 mg (11.4% in orthopedic surgery, 18.8% in plastic surgery).



    • A higher proportion of patients with dosing interruptions was also observed with morphine compared to OLINVYK when the two studies were pooled (morphine 1 mg: 21.5%, OLINVYK 0.35 mg: 13.9%, OLINVYK 0.5 mg: 15.1%).



    • The average cumulative duration of interruptions was also lower for all OLINVYK demand doses in both Phase 3 studies compared to morphine.



    • Using dosing interruptions as a potential surrogate for opioid-induced respiratory depression suggests improved respiratory safety with OLINVYK versus morphine.

    About OLINVYK™ (oliceridine) injection

    OLINVYK is a new chemical entity approved by the FDA in August 2020. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK will not be available for distribution until the United States Drug Enforcement Administration assigns it to its schedule of controlled substances. Please see Important Safety Information, including the BOXED WARNING, and full prescribing information at www.OLINVYK.com.

    About Trevena

    Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

    Forward-Looking Statements

    Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "objective," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," "ongoing," or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Company's clinical trials or any future trials of any of the Company's investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company's assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Company's intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

    For more information, please contact:

    Investor Contact:

    Dan Ferry

    Managing Director

    LifeSci Advisors, LLC



    (617) 430-7576

    Company Contact:

    Bob Yoder

    SVP and Chief Business Officer

    Trevena, Inc.

    (610) 354-8840

     

    Primary Logo

    View Full Article Hide Full Article
  3. --

    TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19

    The Company expects to report topline data in Q1 2021

    --

    CHESTERBROOK, Pa., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced Imperial College London (ICL) has initiated a proof-of-concept study for TRV027 in COVID-19 patients. Through an ongoing collaboration with ICL, the Company is evaluating the potential of TRV027 to treat acute lung damage / abnormal blood clotting associated with COVID-19. ICL is sponsoring…

    --

    TRV027 is a novel AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19

    The Company expects to report topline data in Q1 2021

    --

    CHESTERBROOK, Pa., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced Imperial College London (ICL) has initiated a proof-of-concept study for TRV027 in COVID-19 patients. Through an ongoing collaboration with ICL, the Company is evaluating the potential of TRV027 to treat acute lung damage / abnormal blood clotting associated with COVID-19. ICL is sponsoring and funding the study, with additional support through the British Heart Foundation Centre for Research Excellence Award.

    "I am very pleased that Imperial College London has reached this important milestone of trial initiation," said Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. "As the global search for solutions to combat the COVID-19 pandemic continues, there remains an urgent need for new therapies that can prevent the severe multi-organ damage caused by the virus. TRV027 represents a uniquely targeted approach to potentially treating some of the serious and deadly complications associated with COVID-19."

    In a COVID-19 infection, the SARS-coronavirus-2 binds to and removes the ACE2 protein in the lungs and other organs, resulting in a hormonal imbalance at the AT1 receptor. This results in acute lung damage, which often progresses to acute respiratory distress syndrome (ARDS), as well as abnormal blood clotting throughout the body. TRV027 specifically binds to and rebalances AT1 receptor activation, blocking the damaging pathway that leads to ARDS and abnormal blood clotting conditions such as stroke. Additionally, the unique mechanism of action of TRV027 selectively targets the reparative pathway that improves lung function and promotes anti-inflammatory effects.

    This is a randomized, double-blind, placebo-controlled study that will enroll approximately 60 hospitalized, non-ventilated patients aged 18 or older with a confirmed COVID-19 infection. The primary objective of the study is to evaluate whether TRV027 reduces abnormal clotting associated with COVID-19. The study will also assess the effect of TRV027 on lung function and other clinical outcomes. The Company currently expects to report topline data in Q1 2021.

    About TRV027

    TRV027 is a novel AT1 receptor selective agonist that has previously been studied in 691 individuals. It has demonstrated efficacy, potency, and selectivity at the AT1 receptor in nonclinical studies and has a well-characterized pharmacokinetic profile. In previous clinical trials, there was a low dropout rate associated with TRV027, and no significant safety issues were reported. In April 2020, the Company filed a provisional patent application with the United States Patent and Trademark Office covering the use of TRV027 to treat ARDS and the prevention or treatment of abnormal clotting in COVID-19 patients.

    About Trevena

    Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

    Forward-Looking Statements

    Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "objective," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," "ongoing," or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Company's clinical trials or any future trials of any of the Company's investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company's assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Company's intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

    For more information, please contact:

    Investor Contact:

    Dan Ferry

    Managing Director

    LifeSci Advisors, LLC



    (617) 430-7576

    Company Contact:

    Bob Yoder

    SVP and Chief Business Officer

    Trevena, Inc.

    (610) 354-8840

    Primary Logo

    View Full Article Hide Full Article
  4. --

    $3 million milestone payment for U.S. approval of OLINVYK™ (oliceridine) injection

    Additional approval and commercialization milestone payments expected as well as 10% royalties on net sales in China

    --

    CHESTERBROOK, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it has a received a $3 million milestone payment from its partner in China for the U.S. approval of OLINVYK. Nhwa holds an exclusive license agreement to develop, manufacture, and commercialize OLINVYK in China.

    "With U.S. approval of OLINVYK now in hand, I am pleased that our ex-U.S…

    --

    $3 million milestone payment for U.S. approval of OLINVYK™ (oliceridine) injection

    Additional approval and commercialization milestone payments expected as well as 10% royalties on net sales in China

    --

    CHESTERBROOK, Pa., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced it has a received a $3 million milestone payment from its partner in China for the U.S. approval of OLINVYK. Nhwa holds an exclusive license agreement to develop, manufacture, and commercialize OLINVYK in China.

    "With U.S. approval of OLINVYK now in hand, I am pleased that our ex-U.S. partnerships also continue to make meaningful progress," said Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. "We look forward to supporting Nhwa as they continue to advance OLINVYK towards regulatory approval in China."

    In June 2020, the Company announced that Nhwa had been approved by the Chinese National Medical Products Administration (NMPA) to initiate clinical trials. The Company expects to receive future milestone payments, as well as a 10% royalty on net sales of OLINVYK in China.

    About OLINVYK™ (oliceridine) injection

    OLINVYK is a new chemical entity approved by the FDA in August 2020. It is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. OLINVYK will not be available for distribution until the United States Drug Enforcement Administration assigns it to its schedule of controlled substances. For more information, please visit www.OLINVYK.com.

    About Trevena

    Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

    Forward-Looking Statements

    Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company's strategy, future operations, clinical development and trials of its therapeutic candidates, plans for potential future product candidates, commercialization of approved drug products and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "objective," "predict," "project," "suggest," "target," "potential," "will," "would," "could," "should," "continue," "ongoing," or the negative of these terms or similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of the Company's clinical trials or any future trials of any of the Company's investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including the Company's assessment of the discussions with the FDA or other regulatory agencies about any and all of its programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to the Company's intellectual property; uncertainties related to the ongoing COVID-19 pandemic, other matters that could affect the availability or commercial potential of the Company's therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

    For more information, please contact:

    Investor Contact:

    Dan Ferry

    Managing Director

    LifeSci Advisors, LLC



    (617) 430-7576

    Company Contact:

    Bob Yoder

    SVP and Chief Business Officer

    Trevena, Inc.

    (610) 354-8840 

    Primary Logo

    View Full Article Hide Full Article
  5. CHESTERBROOK, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive Officer, will participate in a fireside chat at the JMP Securities CNS Forum, being held virtually on August 19 - 20, 2020.

    Presentation Details

    Date: Thursday, August 20, 2020
    Time:  12:30 p.m. Eastern Time
    Webcast: https://www.trevena.com/investors/events-presentations/ir-calendar


    About Trevena

    Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company…

    CHESTERBROOK, Pa., Aug. 14, 2020 (GLOBE NEWSWIRE) -- Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Carrie Bourdow, President and Chief Executive Officer, will participate in a fireside chat at the JMP Securities CNS Forum, being held virtually on August 19 - 20, 2020.

    Presentation Details

    Date: Thursday, August 20, 2020
    Time:  12:30 p.m. Eastern Time
    Webcast: https://www.trevena.com/investors/events-presentations/ir-calendar



    About Trevena


    Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with CNS disorders. The Company has one approved product in the U.S., OLINVYK™ (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.   The Company also has four novel and differentiated investigational drug candidates: TRV250 for the acute treatment of migraine, TRV734 for maintenance treatment of opioid use disorder, and TRV027 for acute lung injury / abnormal blood clotting in COVID-19 patients. The Company has also identified TRV045, a novel S1P receptor modulator that may offer a new, non-opioid approach to treating a variety of CNS disorders.

    For more information, please contact:

    Investor Contact:

    Daniel Ferry

    Managing Director

    LifeSci Advisors, LLC

     

    (617) 430-7576

    Company Contact:

    Bob Yoder

    SVP and Chief Business Officer

    Trevena, Inc.

    (610) 354-8840

    Primary Logo

    View Full Article Hide Full Article
View All Trevena Inc. News